me 2303 has been researched along with Experimental Hepatoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoshi, A; Iigo, M; Nakajima, Y; Nishikata, K | 1 |
| Hoshi, A; Iigo, M; Kadosawa, H; Nakajima, S; Nakajima, Y; Nishikata, K | 1 |
2 other study(ies) available for me 2303 and Experimental Hepatoma
| Article | Year |
|---|---|
Effects of anthracycline derivatives on hepatic neoplastic nodules of Lewis lung carcinoma and colon adenocarcinoma 26.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Colonic Neoplasms; Doxorubicin; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Precancerous Conditions | 1991 |
Therapeutic activity and tissue distribution of ME2303, a new anthracycline containing fluorine, and its metabolites in mice bearing hepatic metastases of Lewis lung carcinoma.
Topics: Animals; Bone Marrow; Doxorubicin; Liver; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Tissue Distribution | 1990 |